Nektar Therapeutics (NKTR) Reports Q3 Loss, Tops Revenue Estimates
Portfolio Pulse from
Nektar Therapeutics (NKTR) reported a Q3 loss of $0.18 per share, which was better than the expected loss of $0.23 per share. This is a slight improvement from the $0.19 loss per share reported a year ago.
November 08, 2024 | 12:00 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Nektar Therapeutics reported a Q3 loss of $0.18 per share, beating the Zacks Consensus Estimate of a $0.23 loss. This is a slight improvement from last year's $0.19 loss per share.
Nektar's reported loss per share was better than expected, which is typically seen as a positive indicator for the stock price. The improvement from last year's loss also suggests a positive trend.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100